1-6 of 6
Sheida Hayati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study

Rami S. Komrokji, Manuel Ugidos Guerrero, Guillermo Garcia-Manero, Amer M. Zeidan, Uwe Platzbecker, Sheida Hayati, Sadanand Vodala
Journal: Blood
Blood (2023) 142 (Supplement 1): 4591.
https://doi.org/10.1182/blood-2023-178689
Published: 2023
Journal Articles

Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A Subgroup Analysis from the Phase 3 COMMANDS Trial

Maroof Hasan, Sadanand Vodala, Sheida Hayati, Guillermo Garcia-Manero, Anita K. Gandhi, Rajasekhar N.V.S. Suragani
Journal: Blood
Blood (2023) 142 (Supplement 1): 3214.
https://doi.org/10.1182/blood-2023-178666
Published: 2023
Journal Articles

Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study

Danny Jeyaraju, Sheida Hayati, Niloufar Marsousi, Aaron T. Gerds, Francesco Passamonti, Fabian Sanabria, Sadanand Vodala, Anita K. Gandhi, Rajasekhar N.V.S. Suragani
Journal: Blood
Blood (2023) 142 (Supplement 1): 6330.
https://doi.org/10.1182/blood-2023-182155
Published: 2023
Journal Articles

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Sheida Hayati, Amer M. Zeidan, Guillermo Garcia-Manero, Uwe Platzbecker, Aarif Ahsan, Amit K. Verma, Srinivas Aluri, Manuel Ugidos Guerrero, Anita K. Gandhi, Rajasekhar N.V.S. Suragani, Sadanand Vodala
Journal: Blood
Blood (2023) 142 (Supplement 1): 1845.
https://doi.org/10.1182/blood-2023-178674
Published: 2023
Journal Articles

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Danny Jeyaraju, Sheida Hayati, Jia Wang, Claire N Harrison, Jean-Jacques Kiladjian, Christopher Hernandez, Patrick Brown, Daniel Lopes De Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani
Journal: Blood
Blood (2023) 142 (Supplement 1): 4526.
https://doi.org/10.1182/blood-2023-180419
Published: 2023
Journal Articles

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3865–3867.
https://doi.org/10.1182/blood-2022-166407
Published: 2022